Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database

被引:1
作者
Quinlan, Scott C. [1 ]
Cheng, Wendy Y. [2 ]
Ishihara, Lianna [3 ,5 ]
Irizarry, Michael C. [4 ,6 ]
Holick, Crystal N. [1 ]
Duh, Mei Sheng [2 ]
机构
[1] HealthCore Inc, Wilmington, DE USA
[2] Anal Grp Inc, Boston, MA USA
[3] GlaxoSmithKline Plc, Uxbridge, Middx, England
[4] GlaxoSmithKline Plc, Res Triangle Pk, NC USA
[5] Lundbeck SAS, Paris, France
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
urinary retention; epilepsy; algorithm; pharmacoepidemiology; PARTIAL-ONSET SEIZURES; ADJUNCTIVE THERAPY; ANTIEPILEPTIC DRUGS; POTASSIUM CHANNELS; RETIGABINE; ADULTS; ANTICONVULSANT; EZOGABINE; PROFILE; MG/DAY;
D O I
10.1002/pds.3975
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PurposeThe aim of this study was to develop and validate an insurance claims-based algorithm for identifying urinary retention (UR) in epilepsy patients receiving antiepileptic drugs to facilitate safety monitoring. MethodsData from the HealthCore Integrated Research Database(SM) in 2008-2011 (retrospective) and 2012-2013 (prospective) were used to identify epilepsy patients with UR. During the retrospective phase, three algorithms identified potential UR: (i) UR diagnosis code with a catheterization procedure code; (ii) UR diagnosis code alone; or (iii) diagnosis with UR-related symptoms. Medical records for 50 randomly selected patients satisfying 1 algorithm were reviewed by urologists to ascertain UR status. Positive predictive value (PPV) and 95% confidence intervals (CI) were calculated for the three component algorithms and the overall algorithm (defined as satisfying 1 component algorithms). Algorithms were refined using urologist review notes. In the prospective phase, the UR algorithm was refined using medical records for an additional 150 cases. ResultsIn the retrospective phase, the PPV of the overall algorithm was 72.0% (95%CI: 57.5-83.8%). Algorithm 3 performed poorly and was dropped. Algorithm 1 was unchanged; urinary incontinence and cystitis were added as exclusionary diagnoses to Algorithm 2. The PPV for the modified overall algorithm was 89.2% (74.6-97.0%). In the prospective phase, the PPV for the modified overall algorithm was 76.0% (68.4-82.6%). Upon adding overactive bladder, nocturia and urinary frequency as exclusionary diagnoses, the PPV for the final overall algorithm was 81.9% (73.7-88.4%). ConclusionsThe current UR algorithm yielded a PPV>80% and could be used for more accurate identification of UR among epilepsy patients in a large claims database. Copyright (c) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:413 / 421
页数:9
相关论文
共 14 条
[1]   The descriptive epidemiology of epilepsy-A review [J].
Banerjee, Poonam Nina ;
Filippi, David ;
Hauser, W. Allen .
EPILEPSY RESEARCH, 2009, 85 (01) :31-45
[2]   Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX) [J].
Bialer, Meir ;
Johannessen, Svein I. ;
Levy, Rene H. ;
Perucca, Emilio ;
Tomsone, Torbjorn ;
White, H. Steve .
EPILEPSY RESEARCH, 2009, 83 (01) :1-43
[3]   Retigabine: Chemical synthesis to clinical application [J].
Blackburn-Munro, G ;
Dalby-Brown, W ;
Mirza, NR ;
Mikkelsen, JD ;
Blackbum-Munro, RE .
CNS DRUG REVIEWS, 2005, 11 (01) :1-20
[4]   The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels [J].
Brickel, Neil ;
Gandhi, Paul ;
VanLandingham, Kevan ;
Hammond, Janet ;
DeRossett, Sarah .
EPILEPSIA, 2012, 53 (04) :606-612
[5]  
Brodie MJ, 2008, EPILEPSIA, V49, P110
[6]  
French JA, 2008, EPILEPSIA, V49, P112
[7]   Early identification of refractory epilepsy. [J].
Kwan, P ;
Brodie, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (05) :314-319
[8]   Development of new antiepileptic drugs: challenges, incentives, and recent advances [J].
Perucca, Emilio ;
French, Cqueline ;
Bialer, Meir .
LANCET NEUROLOGY, 2007, 6 (09) :793-804
[9]  
Poole C, 1985, AM J EPIDEMIOL, V122, P1
[10]   Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures [J].
Porter, R. J. ;
Partiot, A. ;
Sachdeo, R. ;
Nohria, V. ;
Alves, W. M. .
NEUROLOGY, 2007, 68 (15) :1197-1204